Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors
NCT ID: NCT01764321
Last Updated: 2020-12-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1723 participants
OBSERVATIONAL
2012-12-31
2020-06-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Certolizumab Pegol treatment
Certolizumab Pegol in combination with at least one Disease Modifying Antirheumatic Drug (DMARD)
No interventions assigned to this group
Other Tumor Necrosis Factor TNF inhibitor treatment
Other subcutaneous (sc) Tumor Necrosis Factor (TNF) inhibitor (Adalimumab, Golimumab, Etanercept) in combination with at least one Disease Modifying Antirheumatic Drug (DMARD)
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Moderate to severe disease activity of RA
* The patient receives Tumor Necrosis Factor (TNF) inhibitor in combination with at least 1 synthetic Disease Modifying Antirheumatic Drug (DMARD)
* The decision to prescribe a TNF inhibitor in combination with DMARD is made by the treating physician, prior to and independently from the decision to include the patient in this Non-Interventional Study (NIS)
* Male or female patients ≥ 18 years of age, considered by the treating physician to be reliable and capable of adhering to the observational plan (eg, able to understand and complete questionnaires)
* The patient personally signed and dated Patient Data Consent Form (PDCF) prior to Visit 2
* Treatment is according to the Summary of Product Characteristics (SmPC)
Exclusion Criteria
* Prior use of any TNF inhibitors (including Adalimumab, Etanercept, Infliximab, Certolizumab, or Golimumab), or other biologic DMARDs (including Abatacept, Rituximab, Tocilizumab, or Anakinra)
* Participation in an investigational study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB Pharma SA
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
UCB Cares
Role: STUDY_DIRECTOR
+1 844 599 2273 (UCB)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
039
Aachen, , Germany
079
Aachen, , Germany
017
Altenburg, , Germany
044
Altenholz, , Germany
082
Amberg, , Germany
030
Bad Bramstedt, , Germany
073
Bad Doberan, , Germany
134
Bad Homburg, , Germany
010
Bad Kreuznach, , Germany
153
Bad Kreuznach, , Germany
023
Bad Nauheim, , Germany
132
Bad Neuenahr-Ahrweiler, , Germany
196
Bad Pyrmont, , Germany
046
Bautzen, , Germany
125
Bautzen, , Germany
031
Bayreuth, , Germany
033
Bayreuth, , Germany
018
Berlin, , Germany
019
Berlin, , Germany
036
Berlin, , Germany
040
Berlin, , Germany
058
Berlin, , Germany
072
Berlin, , Germany
087
Berlin, , Germany
099
Berlin, , Germany
100
Berlin, , Germany
101
Berlin, , Germany
005
Bochum, , Germany
194
Braunschweig, , Germany
021
Burghausen, , Germany
179
Chemnitz, , Germany
075
Cottbus, , Germany
027
Darmstadt, , Germany
062
Donaueschingen, , Germany
089
Dresden, , Germany
110
Dresden, , Germany
063
Düsseldorf, , Germany
014
Elmshorn, , Germany
080
Erfurt, , Germany
142
Erlangen, , Germany
176
Essen, , Germany
008
Frankenberg, , Germany
016
Frankfurt, , Germany
098
Frankfurt, , Germany
054
Freiberg, , Germany
041
Freiburg im Breisgau, , Germany
147
Freiburg im Breisgau, , Germany
188
Friedrichroda, , Germany
140
Geilenkirchen, , Germany
164
Geislingen an der Steige, , Germany
133
Giessen, , Germany
191
Giessen, , Germany
143
Goslar, , Germany
032
Göttingen, , Germany
025
Greifswald, , Germany
029
Halle, , Germany
186
Halle, , Germany
002
Hamburg, , Germany
006
Hamburg, , Germany
052
Hamburg, , Germany
056
Hamburg, , Germany
070
Hamburg, , Germany
107
Hanover, , Germany
136
Hanover, , Germany
048
Heidelberg, , Germany
057
Heidelberg, , Germany
124
Herne, , Germany
043
Hildesheim, , Germany
053
Hofheim, , Germany
092
Hoyerswerda, , Germany
096
Jena, , Germany
180
Karlsruhe, , Germany
184
Kronach, , Germany
004
Leipzig, , Germany
068
Leipzig, , Germany
013
Ludwigsfelde, , Germany
114
Lübeck, , Germany
034
Magdeburg, , Germany
177
Mainz, , Germany
195
Mansfeld, , Germany
028
Marktredwitz, , Germany
049
Mittelherwigsdorf, , Germany
055
Mönchengladbach, , Germany
015
München, , Germany
020
München, , Germany
093
München, , Germany
111
München, , Germany
175
München, , Germany
037
Naunhof, , Germany
047
Neubrandenburg, , Germany
078
Neuss, , Germany
090
Neuss, , Germany
109
Nienburg, , Germany
076
Offenburg, , Germany
035
Planegg, , Germany
097
Plauen, , Germany
051
Potsdam, , Germany
187
Potsdam, , Germany
061
Püttlingen, , Germany
185
Radebeul, , Germany
123
Rendsburg, , Germany
118
Rostock, , Germany
112
Saarbrücken, , Germany
121
Schwerin, , Germany
122
Schwerin, , Germany
144
Schwerin, , Germany
193
Seesen, , Germany
115
Stadtbergen, , Germany
171
Stolberg, , Germany
074
Stuttgart, , Germany
146
Stuttgart, , Germany
085
Traunstein, , Germany
152
Treuenbrietzen, , Germany
009
Tübingen, , Germany
059
Tübingen, , Germany
077
Weener, , Germany
113
Winsen, , Germany
065
Wuppertal, , Germany
106
Würselen, , Germany
042
Würzburg, , Germany
182
Zwickau, , Germany
001
Zwiesel, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RA0097
Identifier Type: -
Identifier Source: org_study_id